Literature DB >> 21358376

Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort.

Rodolphe Thiébaut1, Sophie Matheron, Audrey Taieb, Francoise Brun-Vezinet, Geneviève Chêne, Brigitte Autran.   

Abstract

Among 342 HIV-2-infected patients of the ANRS CO5 HIV-2 cohort, the prevalence of long-term nonprogressors (LTNPs) (i.e. asymptomatic for at least 8 years while maintaining CD4 cell count at least 500 cells/μl) and of HIV controllers (i.e. controlling HIV replication in the absence of antiretroviral treatment for at least 10 years) was 6.1% (95% confidence interval 3.9-9.1) and 9.1% (6.3-12.7), respectively. Most LTNPs (81%) were HIV controllers, whereas only 55% of HIV controllers were LTNPs.

Entities:  

Mesh:

Year:  2011        PMID: 21358376     DOI: 10.1097/QAD.0b013e328344892e

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 2.  Mortality and survival patterns of people living with HIV-2.

Authors:  Boris Tchounga; Didier K Ekouevi; Eric Balestre; François Dabis
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

3.  Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.

Authors:  Dana N Raugi; Selly Ba; Ousseynou Cisse; Khardiata Diallo; Ibrahima Tito Tamba; Cheikh Ndour; Ndeye Mery Dia Badiane; Louise Fortes; Mouhamadou Baïla Diallo; Dominique Faye; Robert A Smith; Fatima Sall; Macoumba Toure; ElHadji Ibrahima Sall; Habibatou Diallo Agne; Khadim Faye; Jean Philippe Diatta; Marie Pierre Sy; Ming Chang; Binetou Diaw; Jacques Sambou; Raphael Bakhoum; Mame Demba Sy; Alassane Niang; Jean Jacques Malomar; Robert W Coombs; Stephen E Hawes; Ibra Ndoye; Nancy B Kiviat; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2021-02-01       Impact factor: 20.999

4.  Novel assays to investigate the mechanisms of latent infection with HIV-2.

Authors:  Michael D Lu; Sushama Telwatte; Nitasha Kumar; Fernanda Ferreira; Holly Anne Martin; Gayatri Nikhila Kadiyala; Adam Wedrychowski; Sara Moron-Lopez; Tsui-Hua Chen; Erin A Goecker; Robert W Coombs; Chuanyi M Lu; Joseph K Wong; Athe Tsibris; Steven A Yukl
Journal:  PLoS One       Date:  2022-04-27       Impact factor: 3.752

5.  An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration.

Authors:  Ashley D Olson; Laurence Meyer; Maria Prins; Rodolphe Thiebaut; Deepti Gurdasani; Marguerite Guiguet; Marie-Laure Chaix; Pauli Amornkul; Abdel Babiker; Manjinder S Sandhu; Kholoud Porter
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

6.  HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells.

Authors:  Lise Chauveau; Isabel Puigdomenech; Diana Ayinde; Ferdinand Roesch; Françoise Porrot; Daniela Bruni; Benoit Visseaux; Diane Descamps; Olivier Schwartz
Journal:  Retrovirology       Date:  2015-01-13       Impact factor: 4.602

7.  Cyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates.

Authors:  João I Mamede; Florence Damond; Ariel de Bernardo; Sophie Matheron; Diane Descamps; Jean-Luc Battini; Marc Sitbon; Valérie Courgnaud
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

8.  Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection.

Authors:  Marco Iannetta; Stéphane Isnard; Jennifer Manuzak; Jean-Baptiste Guillerme; Mathilde Notin; Karine Bailly; Muriel Andrieu; Sonia Amraoui; Lene Vimeux; Suzanne Figueiredo; Bénédicte Charmeteau-de Muylder; Laura Vaton; Etienne X Hatton; Assia Samri; Brigitte Autran; Rodolphe Thiébaut; Nathalie Chaghil; David Glohi; Charlotte Charpentier; Diane Descamps; Françoise Brun-Vézinet; Sophie Matheron; Remi Cheynier; Anne Hosmalin
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

9.  First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).

Authors:  Sophie Matheron; Diane Descamps; Sebastien Gallien; Amel Besseghir; Pierre Sellier; Laurent Blum; Emmanuel Mortier; Charlotte Charpentier; Roland Tubiana; Florence Damond; Gilles Peytavin; Diane Ponscarme; Fideline Collin; Francoise Brun-Vezinet; Genevieve Chene
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

10.  Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.

Authors:  François E Dufrasne; Catherine Lombard; Patrick Goubau; Jean Ruelle
Journal:  Viruses       Date:  2016-10-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.